Opticyte developed breakthrough cell O2 patient monitor for real-time, continuous monitoring of patients who are at high risk of organ failure.
The Cellular O2 Patient Monitor with the help of non-invasive optical spectroscopy technology measures and detects systemic low oxygen levels in cells. The device promises to reduce organ failure by immediately and continuously monitoring cellular oxygen levels during hospitalisation for sepsis, trauma and myocardial infarction.
This new Cell O2 Patient Monitor allows quickly to reach sepsis, trauma, and cardiac surgery patients with organ dysfunction who are on the verge of organ failure.
In U.S, it is estimated that at least 1.7 million adults consists of sepsis, among which 270,000 die as a result every year. To determine organ failure for patients with sepsis, trauma or myocardial infarction, the currently available standard of care needs lab work, blood draw and an estimated two hours of testing time.
U.S. Food and Drug Administration (FDA) grants breakthrough device designation for Cell O2 Patient Monitor to detect organ failure.
